'Cancer: Trials and Tribulations '

Series Name Department of Cancer Studies & Molecular Medicine
Speaker Professor Anne Thomas
Type Lectures & Talks
Starts at Nov 26, 2013 05:30 PM
Ends at Nov 26, 2013 06:30 PM
Venue Ken Edwards Building, Lecture Theatre 1
Open To Public
For Bookings Contact 0116 252 2320

In the last ten years there have been significant changes in the way we manage patients with cancer. Personalising care in terms of chemotherapy delivery is the current vogue. With the new targeted agents we have to reconsider how we evaluate these drugs in clinical studies. Certainly the historical way of using chemotherapy at increasing doses until a dose is found too toxic to use, then declaring that the recommended dose is outdated. Also gone are the large clinical studies including unselected patient populations.  Today our clinical studies look very different. With the targeted agents we select small groups of patients most likely to benefit from therapy according to prognostic and predictive biomarkers.  Consequently we are seeing some great improvements but sadly often benefiting small groups of patients. In addition personalising care for patients is not just about their treatment. It is about individualising their care from consultation through management of toxicities as well.

In this review an outline of cancer studies for patients with solid tumours delivered over the last 10 years, initially through the commercial trial unit and more latterly the Hope Clinical Trials Unit will be given. Novel trial design and endpoints will be discussed and the challenges we face. Work looking at individualising clinic consultations will be presented and strategies to predict toxicities in patient undergoing chemotherapy will be discussed.

More information about this event...

Share this page: